Abstract
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family, which is expressed or highly expressed in a variety of solid tumors, including oral cancers. High EGFR expression has been correlated with tumor size, metastasis and survival. In recent years, EGFR has been considered a promising target for monoclonal antibody therapy. A total of 52 patients with oral squamous cell carcinoma (OSCC) were selected for EGFR and phosphorylated EGFR (p-EGFR) detection. Immunohistochemical staining was performed to evaluate EGFR and p-EGFR expression. Positive EGFR and p-EGFR staining was present in 92.3% (48/52) and 98.0% (51/52) of all cases, respectively. High EGFR and p-EGFR expression was present in 63.4% (33/52) and 69.2% (36/52) of all cases, respectively. EGFR and p-EGFR expression did not correlate with the clinical factors tumor stage, regional lymph node metastasis, or distant metastasis. However, a statistically significant correlation was identified between high EGFR expression and the pathologic factor tumor invasion. As a conclusion, the majority of OSCCs highly express EGFR and p-EGFR, indicating the importance of studying the efficacy of anticancer therapy targeting these signal factors.(Pathology Oncology Research Vol 12, No 2, 87–91)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183–232, 1995
Mendelsohn J, Baselga L: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 14: 2787–2799, 2003
Irish JC, Bernstein A: Oncogenes in head and neck cancer. Laryngoscope 103: 42–52, 1993
Yamamoto E, Kohama G, Iwai M, Hiratsuka H: Mode of invasion, Bleomycin sensitivity and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51: 2175–2180, 1983
Wada T: Nature of mononuclear cell infiltrates in oral squamous cell carcinoma and their clinical significance. Wakayama Med Rep 30: 103–117, 1989
Putti TC, To KF, Hsu HC, et al: Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 41: 144–151, 2002
van Oijen MG, Rijksen G, ten Broek FW, Slootweg PJ: Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse. Oral Dis 4: 4–8, 1998
Wen QH, Nishimura X, Nagayama I, Furukawa M: Expression of EGF, EGFR and PCNA in laryngeal lesions. J Laryngol Otol 109: 630–636, 1995
Lee CS, Redshaw A, Boag G: Epidermal growth factor immunoreactivity in human laryngeal squamous cell carcinoma. Pathology 29: 251–254, 1997
Kearsley JH, Leonard JH, Walsh MD, Wright GR: A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 23: 189–194, 1991
Zheng X, Hu L, Chen F, Christensson B: Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 30: 290–295, 1994
Miyaguchi M, Olofsson J, Hellquist HB: Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol 16: 466–469, 1991
Downward J, Parker P, Waterfield MD: Autophosphorylation sites on the epidermal growth factor receptor. Nature 311: 483–485, 1984
Kanematsu T, Yano S, Uehara H, et al: Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13: 289–298, 2003
Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167, 2000
Kolch W: Meaningful relationships: The regulation of the Ras/Raf/MEK/ ERK pathway by protein interactions. Biochem J 351: 289–305, 2000
Zwick E, Bange J, Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8: 17–23, 2002
Busse D, Doughty RS, Ramsey TT, et al: Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J Biol Chem 275: 6987–6995, 2000
Khazaie K, Schirrmacher V,LichtnerRB: EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12: 255–274, 1993
Storkel S, Reichert T, Reiffen KA, Wagner W: EGFR and PCNA expression in oral squamous cell carcinomas-a valuable tool in estimating the patient’s prognosis. Eur J Cancer B Oral Oncol 29: 273–277, 1993
Xia W, Lau YK, Zhang HZ, et al: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5: 4164–4174, 1999
Christensen ME: The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 45:121–134, 1998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hiraishi, Y., Wada, T., Nakatani, K. et al. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol. Oncol. Res. 12, 87–91 (2006). https://doi.org/10.1007/BF02893450
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893450